Targeting HepG2Sugar Fluorescent Dye Labeled And Anti-cancer Drug Research

Hepatocellular carcinoma (HCC) is a worldwide disease seriously threatening human health. At present, there have been multiple methods to the clinical diagnosis and treatment of HCC. However, due to Lack of effective means for early diagnosis, the disease was always in its middle or late stages when definitely diagnosed. So, early detection and targeting therapy has become the primary concern in the treatment of liver cancer. How to detect and treat targeting liver cancer has become primary problem. In the current paper HepG2cells was used as the main research subject while Asialoglycoprotein receptor (ASGPr), being specifically expressed on the surface of the liver cells, was used as the targeting receptor.In the first part of the research, we have constructed glycosylated fluorescent dye-graphene complex quenched.With the help of certain lectin "turning on" the quenched fluorescence, we established a new optical method for detection of HepG2. Meanwhile, we constructed heavy metal ion "off-on" probe in HepG2cells by the principle of mercury ions enhancing fluorescence of double triazole glycosylated rhodamine probe.The second part of the research focused and developed upon targeted therapy. Histone deacetylase (HDAC) inhibitor is one of the earliest approved epigenetic targeting drug in the treatment of cutaneous T cell lymphoma (CTCL), yet there has been no substantive progress in its application in the treatment of solid tumors.In this paper, we first established a HDAC inhibitor evaluation system in multiple myeloma (MM) with the listed HDAC inhibitor vorinostat (SAHA) being the positive compound. And then established a second positive compound evaluation system on HepG2for activity screening and pharmacological evaluation of other candidate compounds. In addition, we also built novel liposomes with galactolipids in order to deliver small molecule HDAC inhibitors to liver cancer sites and thus establishing a new targeted treatment system of HDAC inhibitors to liver cancer.